Lucid Diagnostics Completes Successful Public Offering for Cancer Prevention Initiative Lucid Diagnostics has successfully closed its public stock offering, raising approximately $16.1 million to enhance its medical diagnostics for cancer prevention.

Lucid Diagnostics Completes Successful Public Offering for Cancer Prevention Initiative #United_States #New_York #Lucid_Diagnostics #EsoGuard_Test #PAVmed_Inc.

Lucid Diagnostics Announces Pricing for New Public Stock Offering as Growth Strategy Continues Lucid Diagnostics has set the price for its public stock offering aimed at supporting cancer prevention efforts. This move is seen as a critical step for the company's growth.

Lucid Diagnostics Announces Pricing for New Public Stock Offering as Growth Strategy Continues #United_States #New_York #Lucid_Diagnostics #EsoGuard_Test #PAVmed_Inc

Lucid Diagnostics Achieves Unprecedented Growth in EsoGuard Testing Volume Lucid Diagnostics reported a remarkable surge in EsoGuard testing with over 4,000 tests conducted in Q4 2024, a significant 45% increase from the previous quarter.

Lucid Diagnostics Achieves Unprecedented Growth in EsoGuard Testing Volume #United_States #New_York #Cancer_Prevention #Lucid_Diagnostics #EsoGuard_Test

Lucid Diagnostics Secures Convertible Debt Refinancing to Enhance Financial Stability and Achieve Milestones Lucid Diagnostics Inc. has successfully completed a convertible debt refinancing, strengthening its financial position and extending its cash runway beyond critical milestones while enhancing shareholder value.

Lucid Diagnostics Secures Convertible Debt Refinancing to Enhance Financial Stability and Achieve Milestones #USA #New_York #Lucid_Diagnostics #Nasdaq_LUCD #EsoGuard_Test